Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

BMC Infectious Diseases

卷:22

Kavitha Saravu¹  Nitin Gupta¹  Prasanth Balasubramanian²  Charan Thej Reddy Vegivinti²  Richa Chibbar³  Praneeth Reddy Keesari⁴  Yashwitha Sai Pulakurthi⁴  Caleb Zinn⁵  Izzet Akosman⁵  J. Karon⁵  Averi Barrett⁵  Lauren Siegel⁵  Kevin M. Kallmes⁵  Hannah Lyons⁵  Nicole Hardy⁵  Ranita Tarchand⁵  Kathryn Cowie⁵  Spandana Chittajallu⁶  Erin Sheffels⁷  Jillienne Touchette⁷  Bernadette Kane⁷  Kirk W. Evanson⁷ 

[1] Department of Infectious Disease, Kasturba Medical College, Manipal, Manipal Academy of Higher Education;

[2] Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine;

[3] Department of Medicine, Lakeridge Health;

[4] Kamineni Academy of Medical Sciences and Research Center;

[5] Nested Knowledge;

[6] Reading Hospital;

[7] Superior Medical Experts;

关键词: Systematic review;    COVID-19;    Antiviral;    SARS-CoV-2;    Therapeutic;    Randomized controlled trial;   

DOI  :  10.1186/s12879-022-07068-0

来源: DOAJ

【 摘 要 】

Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant threat to public health worldwide. The purpose of this study was to review current evidence obtained from randomized clinical trials on the efficacy of antivirals for COVID-19 treatment. Methods A systematic literature search was performed using PubMed to identify randomized controlled trials published up to September 4, 2021 that examined the efficacy of antivirals for COVID-19 treatment. Studies that were not randomized controlled trials or that did not include treatment of COVID-19 with approved antivirals were excluded. Risk of bias was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) method. Due to study heterogeneity, inferential statistics were not performed and data were expressed as descriptive statistics. Results Of the 2,284 articles retrieved, 31 (12,440 patients) articles were included. Overall, antivirals were more effective when administered early in the disease course. No antiviral treatment demonstrated efficacy at reducing COVID-19 mortality. Sofosbuvir/daclatasvir results suggested clinical improvement, although statistical power was low. Remdesivir exhibited efficacy in reducing time to recovery, but results were inconsistent across trials. Conclusions Although select antivirals have exhibited efficacy to improve clinical outcomes in COVID-19 patients, none demonstrated efficacy in reducing mortality. Larger RCTs are needed to conclusively establish efficacy.

【 授权许可】

Unknown